Clinical trials: Inflammation; Skin
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid…
- Trial name
- PREDICTRA (NCT02198651)
- Testing
- Adalimumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 149 people
- Sponsor
- AbbVie
Atopic Dermatitis
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical…
- Trial name
- NCT03703102
- Testing
- KHK4083
- Where
- 58 sites in United States, Canada and 2 more
- Volunteers
- 274 people
- Sponsor
- Kyowa Kirin, Inc.
Atopic Dermatitis
LEO 29102 Cream in the Treatment of Atopic Dermatitis
This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment regimen in mild to moderate atopic dermatitis…
- Trial name
- NCT01037881
- Testing
- LEO 29102, Elidel®
- Where
- 3 sites in Canada, Finland and 1 more
- Volunteers
- 183 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
- Trial name
- NCT04605094
- Testing
- Benralizumab
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118766
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 763 people
- Sponsor
- Pfizer
Allergic Asthma, Atopic Dermatitis
A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
Phase 1 study to evaluate the safety of MEDI4212.
- Conditions
- Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
- Trial name
- NCT01544348
- Testing
- Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous
- Where
- 7 sites in United States
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
- Trial name
- BREEZE-AD-PEDS (NCT03952559)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 78 sites in Argentina, Australia and 15 more
- Volunteers
- 516 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib as monotherapy in participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD1 (NCT03334396)
- Testing
- Baricitinib
- Where
- 93 sites in Czechia, Denmark and 8 more
- Volunteers
- 660 people
- Sponsor
- Eli Lilly and Company
Chemical Injuries, Unspecified Complication of Corneal Transplant
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for…
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid
- Trial name
- NCT01582880
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph B. Ciolino, MD
Bacteremia
A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions
Background: Contaminated blood cultures result in unnecessary antibiotic use, increased length of stay, and additional laboratory tests, all of which increase healthcare costs.
- Trial name
- NCT01216761
- Testing
- Iodine tincture, Chlorhexidine gluconate, Povidone iodine
- Volunteers
- 3,879 people
- Sponsor
- University of Michigan
Atopic Dermatitis
Secukinumab for Treatment of Atopic Dermatitis
Atopic Dermatitis, also known as atopic eczema, or eczema, is a common skin disease that can affect males and females of all ages, but often starts in childhood.
- Trial name
- NCT02594098
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Skin Infection
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA.
- Trial name
- CG400549 (NCT01593761)
- Testing
- CG400549
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CrystalGenomics, Inc.
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
- Trial name
- TRuE-PN2 (NCT05764161)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 76 sites in United States, Australia and 11 more
- Volunteers
- 190 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Eczema
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
- Trial name
- NCT04021862
- Testing
- Bermekimab Monoclonal Antibody
- Where
- 17 sites in United States
- Volunteers
- 87 people
- Sponsor
- Janssen Research & Development, LLC
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Abscess, Wound Infection
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT02127970
- Testing
- Dalbavancin
- Where
- 78 sites in United States, Bulgaria and 10 more
- Volunteers
- 698 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.
- Trial name
- NCT03359356
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Molluscum Contagiosum
Cantharidin Application in Molluscum Patients
This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum.
- Trial name
- CAMP-2 (NCT03377803)
- Testing
- VP-102 - Cantharidin, Topical Film Forming Solution
- Where
- 15 sites in United States
- Volunteers
- 262 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo